

Antonia Vlahou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8753018/publications.pdf>

Version: 2024-02-01

168
papers

7,021
citations

66343

42
h-index

74163

75
g-index

185
all docs

185
docs citations

185
times ranked

8388
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of a Novel Proteomic Approach for the Detection of Transitional Cell Carcinoma of the Bladder in Urine. <i>American Journal of Pathology</i> , 2001, 158, 1491-1502.	3.8	408
2	Recommendations for Biomarker Identification and Qualification in Clinical Proteomics. <i>Science Translational Medicine</i> , 2010, 2, 46ps42.	12.4	273
3	Molecular and Proteomic Characterization of Human Mesenchymal Stem Cells Derived from Amniotic Fluid: Comparison to Bone Marrow Mesenchymal Stem Cells. <i>Stem Cells and Development</i> , 2007, 16, 931-952.	2.1	268
4	Secretome proteomics for discovery of cancer biomarkers. <i>Journal of Proteomics</i> , 2010, 73, 2291-2305.	2.4	225
5	Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1999-2010.	6.1	205
6	Technical aspects and inter-laboratory variability in native peptide profiling: The CE-MS experience. <i>Clinical Biochemistry</i> , 2013, 46, 432-443.	1.9	181
7	Proteomic approaches to biomarker discovery in prostate and bladder cancers. <i>Proteomics</i> , 2001, 1, 1264-1270.	2.2	159
8	Implementation of proteomic biomarkers: making it work. <i>European Journal of Clinical Investigation</i> , 2012, 42, 1027-1036.	3.4	151
9	Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. <i>Proteomics - Clinical Applications</i> , 2010, 4, 464-478.	1.6	139
10	Diagnosis of Ovarian Cancer Using Decision Tree Classification of Mass Spectral Data. <i>Journal of Biomedicine and Biotechnology</i> , 2003, 2003, 308-314.	3.0	134
11	A Novel Approach Toward Development of a Rapid Blood Test for Breast Cancer. <i>Clinical Breast Cancer</i> , 2003, 4, 203-209.	2.4	128
12	Stem cells: Insights into the secretome. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2013, 1834, 2380-2384.	2.3	122
13	Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. <i>Cancer</i> , 2004, 100, 1814-1822.	4.1	110
14	Addressing the Challenge of Defining Valid Proteomic Biomarkers and Classifiers. <i>BMC Bioinformatics</i> , 2010, 11, 594.	2.6	108
15	Proteasix: A tool for automated and large-scale prediction of proteases involved in naturally occurring peptide generation. <i>Proteomics</i> , 2013, 13, 1077-1082.	2.2	104
16	Proteomic biomarkers in kidney disease: issues in development and implementation. <i>Nature Reviews Nephrology</i> , 2015, 11, 221-232.	9.6	101
17	Prediction of Muscle-invasive Bladder Cancer Using Urinary Proteomics. <i>Clinical Cancer Research</i> , 2009, 15, 4935-4943.	7.0	97
18	Profilin 1 is a Potential Biomarker for Bladder Cancer Aggressiveness. <i>Molecular and Cellular Proteomics</i> , 2012, 11, M111.009449.	3.8	97

#	ARTICLE	IF	CITATIONS
19	Search for Potential Markers for Prostate Cancer Diagnosis, Prognosis and Treatment in Clinical Tissue Specimens Using Amine-Specific Isobaric Tagging (iTRAQ) with Two-Dimensional Liquid Chromatography and Tandem Mass Spectrometry. <i>Journal of Proteome Research</i> , 2008, 7, 3146-3158.	3.7	92
20	Comparative Analysis of Label-Free and 8-Plex iTRAQ Approach for Quantitative Tissue Proteomic Analysis. <i>PLoS ONE</i> , 2015, 10, e0137048.	2.5	92
21	Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study. <i>Clinical Cancer Research</i> , 2016, 22, 4077-4086.	7.0	90
22	NADPH oxidases as drug targets and biomarkers in neurodegenerative diseases: What is the evidence?. <i>Free Radical Biology and Medicine</i> , 2017, 112, 387-396.	2.9	88
23	A Tumor-Protective Role for Human Kallikrein-Related Peptidase 6 in Breast Cancer Mediated by Inhibition of Epithelial-to-Mesenchymal Transition. <i>Cancer Research</i> , 2009, 69, 3779-3787.	0.9	82
24	In vitro and in vivo properties of distinct populations of amniotic fluid mesenchymal progenitor cells. <i>Journal of Cellular and Molecular Medicine</i> , 2011, 15, 1896-1913.	3.6	79
25	Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker. <i>Kidney International Reports</i> , 2017, 2, 1066-1075.	0.8	77
26	A urinary proteome-based classifier for the early detection of decline in glomerular filtration. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw239.	0.7	73
27	Proteomic approaches in the search for disease biomarkers. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 814, 11-19.	2.3	71
28	Developing proteomic biomarkers for bladder cancer: towards clinical application. <i>Nature Reviews Urology</i> , 2015, 12, 317-330.	3.8	69
29	CE-MS based proteomics in biomarker discovery and clinical application. <i>Proteomics - Clinical Applications</i> , 2015, 9, 322-334.	1.6	68
30	Association of kidney fibrosis with urinary peptides: a path towards non-invasive liquid biopsies?. <i>Scientific Reports</i> , 2017, 7, 16915.	3.3	67
31	A Novel Approach Toward Development of a Rapid Blood Test for Breast Cancer. <i>Clinical Breast Cancer</i> , 2003, 4, 203-209.	2.4	67
32	Discovery and validation of urinary biomarkers for detection of renal cell carcinoma. <i>Journal of Proteomics</i> , 2014, 98, 44-58.	2.4	64
33	New insights in molecular mechanisms involved in chronic kidney disease using high-resolution plasma proteome analysis. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1842-1852.	0.7	64
34	Characterization of the human urine proteome by preparative electrophoresis in combination with 2-DE. <i>Proteomics</i> , 2006, 6, 4346-4355.	2.2	62
35	Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw337.	0.7	62
36	Evaluation of the Zucker Diabetic Fatty (ZDF) Rat as a Model for Human Disease Based on Urinary Peptidomic Profiles. <i>PLoS ONE</i> , 2012, 7, e51334.	2.5	59

#	ARTICLE	IF	CITATIONS
37	Desmin and α -B-crystallin interplay in maintenance of mitochondrial homeostasis and cardiomyocyte survival. <i>Journal of Cell Science</i> , 2016, 129, 3705-3720.	2.0	59
38	Proteomics biomarkers for solid tumors: Current status and future prospects. <i>Mass Spectrometry Reviews</i> , 2019, 38, 49-78.	5.4	53
39	Human Amniotic Fluid-Derived Mesenchymal Stem Cells As Therapeutic Vehicles: A Novel Approach For the Treatment of Bladder Cancer. <i>Stem Cells and Development</i> , 2012, 21, 1097-1111.	2.1	52
40	Plasma proteomic analysis reveals altered protein abundances in cardiovascular disease. <i>Journal of Translational Medicine</i> , 2018, 16, 104.	4.4	48
41	Data Sharing Under the General Data Protection Regulation. <i>Hypertension</i> , 2021, 77, 1029-1035.	2.7	47
42	Protein Profiling in Urine for the Diagnosis of Bladder Cancer. <i>Clinical Chemistry</i> , 2004, 50, 1438-1441.	3.2	46
43	Overexpression of α -defensin is associated with bladder cancer invasiveness. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006, 24, 97-108.	1.6	46
44	SRM/MRM targeted proteomics as a tool for biomarker validation and absolute quantification in human urine. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 1441-1454.	3.1	46
45	Analysis of Secreted Proteins for the Study of Bladder Cancer Cell Aggressiveness. <i>Journal of Proteome Research</i> , 2010, 9, 3243-3259.	3.7	44
46	Chronic Empagliflozin Treatment Reduces Myocardial Infarct Size in Nondiabetic Mice Through STAT-3-Mediated Protection on Microvascular Endothelial Cells and Reduction of Oxidative Stress. <i>Antioxidants and Redox Signaling</i> , 2021, 34, 551-571.	5.4	44
47	Marked Defects in the Expression and Glycosylation of α -2-HS Glycoprotein/Fetuin-A in Plasma from Neonates with Intrauterine Growth Restriction. <i>Molecular and Cellular Proteomics</i> , 2008, 7, 591-599.	3.8	43
48	Capillary zone electrophoresis on-line coupled to mass spectrometry: A perspective application for clinical proteomics. <i>Proteomics - Clinical Applications</i> , 2015, 9, 453-468.	1.6	43
49	Very early and transient vegetal-plate expression of SpKrox1, a Kr ^{1/4} ppel/Krox gene from <i>Strongylocentrotus purpuratus</i> . <i>Mechanisms of Development</i> , 1996, 60, 185-195.	1.7	41
50	Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non-muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1061-1068.	1.6	39
51	Cervical Cancer Cell Line Secretome Highlights the Roles of Transforming Growth Factor-Beta-Induced Protein ig-h3, Peroxiredoxin-2, and NRF2 on Cervical Carcinogenesis. <i>BioMed Research International</i> , 2017, 2017, 1-15.	1.9	39
52	Comparison of Depletion Strategies for the Enrichment of Low-Abundance Proteins in Urine. <i>PLoS ONE</i> , 2015, 10, e0133773.	2.5	39
53	New Selective Peptidyl Di(chlorophenyl) Phosphonate Esters for Visualizing and Blocking Neutrophil Proteinase 3 in Human Diseases. <i>Journal of Biological Chemistry</i> , 2014, 289, 31777-31791.	3.4	38
54	Comparison of Urine and Plasma Peptidome Indicates Selectivity in Renal Peptide Handling. <i>Proteomics - Clinical Applications</i> , 2018, 12, e1700163.	1.6	38

#	ARTICLE	IF	CITATIONS
55	Urinary peptides in heart failure: a link to molecular pathophysiology. <i>European Journal of Heart Failure</i> , 2021, 23, 1875-1887.	7.1	37
56	Systems biology: opening new avenues in clinical research. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1015-1018.	0.7	36
57	Establishment of a European Network for Urine and Kidney Proteomics. <i>Journal of Proteomics</i> , 2008, 71, 490-492.	2.4	35
58	Cost-effectiveness of screening type 2 diabetes patients for chronic kidney disease progression with the CKD273 urinary peptide classifier as compared to urinary albumin excretion. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 441-449.	0.7	35
59	Proteome-based classification of Nonmuscle Invasive Bladder Cancer. <i>International Journal of Cancer</i> , 2020, 146, 281-294.	5.1	35
60	A combinatorial approach of Proteomics and Systems Biology in unravelling the mechanisms of acute kidney injury (AKI): involvement of NMDA receptor GRIN1 in murine AKI. <i>BMC Systems Biology</i> , 2013, 7, 110.	3.0	34
61	Considerations on the use of urine markers in the management of patients with high-grade non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1069-1077.	1.6	34
62	Proteomics in cardiovascular disease: recent progress and clinical implication and implementation. <i>Expert Review of Proteomics</i> , 2017, 14, 117-136.	3.0	34
63	High-Throughput LC-MS/MS Proteomic Analysis of a Mouse Model of Mesiotemporal Lobe Epilepsy Predicts Microglial Activation Underlying Disease Development. <i>Journal of Proteome Research</i> , 2016, 15, 1546-1562.	3.7	33
64	Biomarkers for bladder cancer aggressiveness. <i>Current Opinion in Urology</i> , 2012, 22, 390-396.	1.8	32
65	Subtle proteome differences identified between post-dormant vegetative and floral peach buds. <i>Journal of Proteomics</i> , 2011, 74, 607-619.	2.4	31
66	Clinical proteomics in obstetrics and neonatology. <i>Expert Review of Proteomics</i> , 2014, 11, 75-89.	3.0	31
67	Identification of ageing-associated naturally occurring peptides in human urine. <i>Oncotarget</i> , 2015, 6, 34106-34117.	1.8	31
68	Zinc β -glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer. <i>BJU International</i> , 2012, 110, E688-E693.	2.5	30
69	Analysis of the urine proteome via a combination of multi-dimensional approaches. <i>Proteomics</i> , 2012, 12, 391-400.	2.2	30
70	Epidemiologic Design and Analysis for Proteomic Studies: A Primer on -Omic Technologies. <i>American Journal of Epidemiology</i> , 2015, 181, 635-647.	3.4	30
71	Sample preparation and bioinformatics in MALDI profiling of urinary proteins. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 853, 20-30.	2.3	29
72	TiO ₂ -ZrO ₂ affinity chromatography polymeric microchip for phosphopeptide enrichment and separation. <i>Lab on A Chip</i> , 2011, 11, 3113.	6.0	29

#	ARTICLE	IF	CITATIONS
73	Urinary peptidomics analysis reveals proteases involved in diabetic nephropathy. <i>Scientific Reports</i> , 2017, 7, 15160.	3.3	28
74	Urinary CE-MS peptide marker pattern for detection of solid tumors. <i>Scientific Reports</i> , 2018, 8, 5227.	3.3	28
75	Proteomics approaches in cervical cancer: focus on the discovery of biomarkers for diagnosis and drug treatment monitoring. <i>Expert Review of Proteomics</i> , 2016, 13, 731-745.	3.0	27
76	Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention. <i>Oncotarget</i> , 2017, 8, 69435-69455.	1.8	27
77	Functional secretome analysis reveals Annexin-A1 as important paracrine factor derived from fetal mesenchymal stem cells in hepatic regeneration. <i>EBioMedicine</i> , 2019, 45, 542-552.	6.1	27
78	Analytical Performance of ELISA Assays in Urine: One More Bottleneck towards Biomarker Validation and Clinical Implementation. <i>PLoS ONE</i> , 2016, 11, e0149471.	2.5	27
79	Chromosomal and proteome analysis of a new T24-based cell line model for aggressive bladder cancer. <i>Proteomics</i> , 2009, 9, 287-298.	2.2	26
80	Clinical applications of capillary electrophoresis coupled to mass spectrometry in biomarker discovery: Focus on bladder cancer. <i>Proteomics - Clinical Applications</i> , 2013, 7, 779-793.	1.6	26
81	The urinary proteomics classifier chronic kidney disease 273 predicts cardiovascular outcome in patients with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 811-818.	0.7	26
82	Characterization and comparative performance of lentiviral vector preparations concentrated by either one-step ultrafiltration or ultracentrifugation. <i>Virus Research</i> , 2013, 175, 1-11.	2.2	25
83	Microhematuria assessment an IBCN consensus-Based upon a critical review of current guidelines. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 437-451.	1.6	25
84	Systems biology identifies cytosolic PLA2 as a target in vascular calcification treatment. <i>JCI Insight</i> , 2019, 4, .	5.0	25
85	Urinary proteomics and molecular determinants of chronic kidney disease: possible link to proteases. <i>Expert Review of Proteomics</i> , 2014, 11, 535-548.	3.0	24
86	Ten Years of Proteomics in Bladder Cancer: Progress and Future Directions. <i>Bladder Cancer</i> , 2017, 3, 1-18.	0.4	24
87	Back to the future in bladder cancer research. <i>Expert Review of Proteomics</i> , 2011, 8, 295-297.	3.0	23
88	Proteomics based identification of KDM5 histone demethylases associated with cardiovascular disease. <i>EBioMedicine</i> , 2019, 41, 91-104.	6.1	23
89	Challenges of using mass spectrometry as a bladder cancer biomarker discovery platform. <i>World Journal of Urology</i> , 2008, 26, 67-74.	2.2	22
90	Systems biology to battle vascular disease. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1019-1022.	0.7	22

#	ARTICLE	IF	CITATIONS
91	Proteome-Based Systems Biology Analysis of the Diabetic Mouse Aorta Reveals Major Changes in Fatty Acid Biosynthesis as Potential Hallmark in Diabetes Mellitusâ€Associated Vascular Disease. <i>Circulation: Cardiovascular Genetics</i> , 2014, 7, 161-170.	5.1	22
92	Biological Sample Collection for Clinical Proteomics: Existing SOPs. <i>Methods in Molecular Biology</i> , 2015, 1243, 3-27.	0.9	22
93	Microbiome in Chronic Kidney Disease (CKD): An Omics Perspective. <i>Toxins</i> , 2022, 14, 176.	3.4	22
94	A Novel Sea Urchin Nuclear Receptor Encoded by Alternatively Spliced Maternal RNAs. <i>Developmental Biology</i> , 1996, 177, 371-382.	2.0	21
95	Improving peptide relative quantification in MALDI-TOF MS for biomarker assessment. <i>Proteomics</i> , 2013, 13, 2967-2975.	2.2	21
96	Clinical Proteomics for Precision Medicine: The Bladder Cancer Case. <i>Proteomics - Clinical Applications</i> , 2018, 12, 1700074.	1.6	21
97	Proteomics Analysis of Formalin Fixed Paraffin Embedded Tissues in the Investigation of Prostate Cancer. <i>Journal of Proteome Research</i> , 2020, 19, 2631-2642.	3.7	21
98	Cardioprotection by selective SGLT-2 inhibitors in a non-diabetic mouse model of myocardial ischemia/reperfusion injury: a class or a drug effect?. <i>Basic Research in Cardiology</i> , 2022, 117, 27.	5.9	21
99	Urine proteomics in kidney and urogenital diseases: Moving towards clinical applications. <i>Proteomics - Clinical Applications</i> , 2011, 5, 256-268.	1.6	20
100	IMAC Fractionation in Combination with LCâ€MS Reveals H2B and NIF-1 Peptides As Potential Bladder Cancer Biomarkers. <i>Journal of Proteome Research</i> , 2013, 12, 3969-3979.	3.7	20
101	Drug repurposing in oncology. <i>Lancet Oncology</i> , The, 2020, 21, e543.	10.7	20
102	Putting value in biomarker research and reporting. <i>Journal of Proteomics</i> , 2014, 96, A1-A3.	2.4	19
103	Comparison of higher energy collisional dissociation and collisionâ€induced dissociation MS/MS sequencing methods for identification of naturally occurring peptides in human urine. <i>Proteomics - Clinical Applications</i> , 2015, 9, 531-542.	1.6	19
104	Silencing of Profilin-1 suppresses cell adhesion and tumor growth via predicted alterations in integrin and Ca ²⁺ signaling in T24M-based bladder cancer models. <i>Oncotarget</i> , 2016, 7, 70750-70768.	1.8	19
105	Drug Resistance in Natural Isolates of <i>Leishmania donovani</i> s.l. Promastigotes Is Dependent of Pgp170 Expression. <i>PLoS ONE</i> , 2013, 8, e65467.	2.5	18
106	GeLC-MS: A Sample Preparation Method for Proteomics Analysis of Minimal Amount of Tissue. <i>Methods in Molecular Biology</i> , 2017, 1788, 165-175.	0.9	18
107	Advances in urinary proteome analysis and applications in systems biology. <i>Bioanalysis</i> , 2014, 6, 2549-2569.	1.5	17
108	The use of urinary proteomics in the assessment of suitability of mouse models for ageing. <i>PLoS ONE</i> , 2017, 12, e0166875.	2.5	17

#	ARTICLE	IF	CITATIONS
109	Urinary Glycopeptide Analysis for the Investigation of Novel Biomarkers. <i>Proteomics - Clinical Applications</i> , 2019, 13, e1800111.	1.6	17
110	Multiplexed MRM-based protein quantification of putative prognostic biomarkers for chronic kidney disease progression in plasma. <i>Scientific Reports</i> , 2020, 10, 4815.	3.3	17
111	Urinary peptidomic profiles to address age-related disabilities: a prospective population study. <i>The Lancet Healthy Longevity</i> , 2021, 2, e690-e703.	4.6	17
112	Identification of novel molecular signatures of IgA nephropathy through an integrative -omics analysis. <i>Scientific Reports</i> , 2017, 7, 9091.	3.3	16
113	Applications of multiple reaction monitoring targeted proteomics assays in human plasma. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 499-515.	3.1	15
114	Development and Validation of Multiple Reaction Monitoring (MRM) Assays for Clinical Applications. <i>Methods in Molecular Biology</i> , 2019, 1959, 205-223.	0.9	15
115	Collagen-Derived Peptides in CKD: A Link to Fibrosis. <i>Toxins</i> , 2022, 14, 10.	3.4	15
116	Urine Sample Preparation and Protein Profiling by Two-Dimensional Electrophoresis and Matrix-Assisted Laser Desorption Ionization Time of Flight Mass Spectroscopy. <i>Methods in Molecular Biology</i> , 2008, 428, 141-157.	0.9	14
117	Analysis of urinary cathepsin C for diagnosing Papillon-Lévy syndrome. <i>FEBS Journal</i> , 2016, 283, 498-509.	4.7	14
118	Connectivity mapping of glomerular proteins identifies dimethylaminoparthenolide as a new inhibitor of diabetic kidney disease. <i>Scientific Reports</i> , 2020, 10, 14898.	3.3	14
119	Network views for personalized medicine. <i>Proteomics - Clinical Applications</i> , 2013, 7, 384-387.	1.6	13
120	Redox proteomics: from residue modifications to putative biomarker identification by gel- and LC-MS-based approaches. <i>Expert Review of Proteomics</i> , 2013, 10, 537-549.	3.0	13
121	Insights into Biomechanical and Proteomic Characteristics of Small Diameter Vascular Grafts Utilizing the Human Umbilical Artery. <i>Biomedicines</i> , 2020, 8, 280.	3.2	13
122	Protein Interactome of Muscle Invasive Bladder Cancer. <i>PLoS ONE</i> , 2015, 10, e0116404.	2.5	12
123	Integrative analysis of extracellular and intracellular bladder cancer cell line proteome with transcriptome: improving coverage and validity of -omics findings. <i>Scientific Reports</i> , 2016, 6, 25619.	3.3	12
124	Short Term Results of Fibrin Gel Obtained from Cord Blood Units: A Preliminary in Vitro Study. <i>Bioengineering</i> , 2019, 6, 66.	3.5	12
125	Urinary peptide panel for prognostic assessment of bladder cancer relapse. <i>Scientific Reports</i> , 2019, 9, 7635.	3.3	12
126	A Novel Pipeline for Drug Repurposing for Bladder Cancer Based on Patients' Omics Signatures. <i>Cancers</i> , 2020, 12, 3519.	3.7	12

#	ARTICLE	IF	CITATIONS
127	Molecular Changes in Tissue Proteome during Prostate Cancer Development: Proof-of-Principle Investigation. <i>Diagnostics</i> , 2020, 10, 655.	2.6	12
128	Urine peptidome in combination with transcriptomics analysis highlights MMP7, MMP14 and PCSK5 for further investigation in chronic kidney disease. <i>PLoS ONE</i> , 2022, 17, e0262667.	2.5	12
129	Evaluation of Peripheral Blood and Cord Blood Platelet Lysates in Isolation and Expansion of Multipotent Mesenchymal Stromal Cells. <i>Bioengineering</i> , 2018, 5, 19.	3.5	11
130	Impairment of chaperone-mediated autophagy affects neuronal homeostasis through altered expression of DJ-1 and CRMP-2 proteins. <i>Molecular and Cellular Neurosciences</i> , 2019, 95, 1-12.	2.2	11
131	The family of 14â€³ proteins and specifically 14â€³ are upâ€³regulated during the development of renal pathologies. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 4139-4149.	3.6	10
132	Mining the Biomarker Potential of the Urine Peptidome: From Amino Acids Properties to Proteases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5940.	4.1	10
133	Serum and urinary biomarkers of collagen typeâ€³ turnover predict prognosis in patients with heart failure. <i>Clinical and Translational Medicine</i> , 2021, 11, e267.	4.0	10
134	2nd Combined Working Group and Management Committee Meeting of Urine and Kidney Proteomics COST Action 29â€³30 March 2009, Nafplio, Greece. <i>Proteomics - Clinical Applications</i> , 2009, 3, 1017-1022.	1.6	9
135	Urinary Proteomics in Predicting Heart Transplantation Outcomes (uPROPHET)â€³Rationale and database description. <i>PLoS ONE</i> , 2017, 12, e0184443.	2.5	9
136	Subcellular Trafficking of the Nuclear Receptor COUP-TF in the Early Embryonic Cell Cycle. <i>Developmental Biology</i> , 2000, 218, 284-298.	2.0	8
137	Proteomic Feature Maps: A new visualization approach in proteomics analysis. <i>Journal of Biomedical Informatics</i> , 2009, 42, 644-653.	4.3	8
138	Tissue proteomics studies in the investigation of prostate cancer. <i>Expert Review of Proteomics</i> , 2018, 15, 593-611.	3.0	8
139	Fetal Mesenchymal Stem Cells in Cancer Therapy. <i>Current Stem Cell Research and Therapy</i> , 2013, 8, 133-143.	1.3	8
140	PeptiCKDdbâ€³ peptide- and protein-centric database for the investigation of genesis and progression of chronic kidney disease. <i>Database: the Journal of Biological Databases and Curation</i> , 2016, 2016, baw128.	3.0	7
141	Diagnostic and Prognostic Performance of Secreted Protein Acidic and Rich in Cysteine (SPARC) Assay for Detecting Primary and Recurrent Urinary Bladder Cancer. <i>Proteomics - Clinical Applications</i> , 2019, 13, 1800148.	1.6	7
142	Implementation of Clinical Proteomics: A Step Closer to Personalized Medicine?. <i>Proteomics - Clinical Applications</i> , 2019, 13, e1800088.	1.6	7
143	Urine peptidome analysis in cardiorenal syndrome reflects molecular processes. <i>Scientific Reports</i> , 2021, 11, 16219.	3.3	7
144	Protein biomarkers for cardiorenal syndrome. <i>Expert Review of Proteomics</i> , 2019, 16, 325-336.	3.0	6

#	ARTICLE	IF	CITATIONS
145	Application of a Novel Protein Chip Mass Spectrometry Technology for the Identification of Bladder Cancer-Associated Biomarkers. , 2003, 539, 47-60.		6
146	Effect of Heme Oxygenase-1 Deficiency on Glomerular Proteomics. American Journal of Nephrology, 2016, 43, 441-450.	3.1	5
147	RGS14414-Mediated Activation of the 14-3-3 σ in Rodent Perirhinal Cortex Induces Dendritic Arborization, an Increase in Spine Number, Long-Lasting Memory Enhancement, and the Prevention of Memory Deficits. Cerebral Cortex, 2022, 32, 1894-1910.	2.9	5
148	Molecular Mapping of Urinary Complement Peptides in Kidney Diseases. Proteomes, 2021, 9, 49.	3.5	5
149	Computational Methods and Algorithms for Mass-Spectrometry Based Differential Proteomics. Current Proteomics, 2007, 4, 223-234.	0.3	4
150	BcCluster: A Bladder Cancer Database at the Molecular Level. Bladder Cancer, 2016, 2, 65-76.	0.4	4
151	Proteomic Analysis of Mouse Kidney Tissue Associates Peroxisomal Dysfunction with Early Diabetic Kidney Disease. Biomedicines, 2022, 10, 216.	3.2	4
152	Validation of diagnostic nomograms based on CE-MS urinary biomarkers to detect clinically significant prostate cancer. World Journal of Urology, 2022, 40, 2195-2203.	2.2	4
153	Renal and Urinary Proteomics. Proteomics - Clinical Applications, 2011, 5, 211-213.	1.6	3
154	Urinary-Based Markers for Bladder Cancer Detection. Soci�t� Internationale D'urologie Journal, 2020, 1, 49-61.	0.4	3
155	Gene Expression Monotonicity across Bladder Cancer Stages Informs on the Molecular Pathogenesis and Identifies a Prognostic Eight-Gene Signature. Cancers, 2022, 14, 2542.	3.7	3
156	Application of Preparative Electrophoresis for Clinical Proteomics in Urine: Is it Feasible?. Journal of Medical Biochemistry, 2009, 28, 268-273.	1.7	2
157	'Brukin2D': a 2D visualization and comparison tool for LC-MS data. BMC Bioinformatics, 2009, 10, S12.	2.6	2
158	Deciphering the disease-related molecular networks using urine proteomics. TrAC - Trends in Analytical Chemistry, 2017, 94, 200-209.	11.4	2
159	Developing Novel Drug Candidates and Repurposed Drugs for Prostate Cancer Based on Molecular Profiles. Current Medicinal Chemistry, 2021, 28, 8392-8415.	2.4	2
160	Proteomic approaches to biomarker discovery in prostate and bladder cancers. Proteomics, 2001, 1, 1264-1270.	2.2	2
161	Targeting the Proteome of Cellular Fractions: Focus on Secreted Proteins. Methods in Molecular Biology, 2015, 1243, 29-41.	0.9	1
162	Taking the next step��Advancing bladder cancer management. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 435-436.	1.6	1

#	ARTICLE	IF	CITATIONS
163	In Situ Peroxidase Labeling Followed by Mass-Spectrometry Reveals TIA1 Interactome. <i>Biology</i> , 2022, 11, 287.	2.8	1
164	APEX2-Mediated Proximity Labeling Resolves the DDIT4-Interacting Proteome. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5189.	4.1	1
165	FP268 MOLECULAR SIMILARITY OF RENAL AGEING AND CKD REVEALED BY URINARY PROTEOMICS. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii156-iii157.	0.7	0
166	Redox Analysis of Atherosclerotic : Application of the "œ"Method. <i>Methods in Molecular Biology</i> , 2022, 2419, 629-644.	0.9	0
167	MO379: Collagen-Derived Peptides in CKD: A Link to Fibrosis. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
168	Abstract 13262: Improved Rabbit Model of Calcific Aortic Valve Disease Induces Severe Medial Calcification and Stenosis Equivalent to Human Disease. <i>Circulation</i> , 2021, 144, .	1.6	0